Medical treatment for early pregnancy loss following in vitro fertilization compared to spontaneous pregnancies.
Early pregnancy loss
In vitro fertilization
Misoprostol
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
15
08
2023
accepted:
09
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Misoprostol is a well-studied medical treatment for early pregnancy loss (EPL), with success rates ranging between 70 and 90%. However, treatment failure is associated with major patient discomfort, including the need for surgical intervention to evacuate the uterus. It was previously reported that medical treatment was especially successful among women who conceived after in vitro fertilization (IVF). We aimed to study if there is a difference in rates of medical treatment failures for EPL between pregnancies conceived by IVF and spontaneous pregnancies. In this retrospective cohort study, we included all women who underwent medical treatment for EPL at our institute between 07/2015 and 12/2020. Treatment outcome was compared between IVF and spontaneous pregnancies. Treatment failure was defined as a need for surgical intervention, namely, dilation & curettage (D&C) and/or hysteroscopy, due to retained products of conception, which was defined as a gestational sac or endometrial thickness greater than 15 mm in a TVS scan. Overall, 775 patients were included, of which 195 (169/775 = 25.1%) ultimately required surgical intervention. There was no difference between the study groups in the rate of treatment failure. However, among IVF pregnancies, the rate of emergency D&C was lower (3.6% vs. 9.8%, p = 0.001), compared to spontaneous group. In cases of medical treatment for EPL, IVF pregnancies had no differences in rates of treatment failure compared to spontaneous pregnancies. That being said, IVF pregnancies have lower chances to undergo emergency D&C, compared to spontaneous pregnancies.
Sections du résumé
BACKGROUND
BACKGROUND
Misoprostol is a well-studied medical treatment for early pregnancy loss (EPL), with success rates ranging between 70 and 90%. However, treatment failure is associated with major patient discomfort, including the need for surgical intervention to evacuate the uterus. It was previously reported that medical treatment was especially successful among women who conceived after in vitro fertilization (IVF). We aimed to study if there is a difference in rates of medical treatment failures for EPL between pregnancies conceived by IVF and spontaneous pregnancies.
METHODS
METHODS
In this retrospective cohort study, we included all women who underwent medical treatment for EPL at our institute between 07/2015 and 12/2020. Treatment outcome was compared between IVF and spontaneous pregnancies. Treatment failure was defined as a need for surgical intervention, namely, dilation & curettage (D&C) and/or hysteroscopy, due to retained products of conception, which was defined as a gestational sac or endometrial thickness greater than 15 mm in a TVS scan.
RESULTS
RESULTS
Overall, 775 patients were included, of which 195 (169/775 = 25.1%) ultimately required surgical intervention. There was no difference between the study groups in the rate of treatment failure. However, among IVF pregnancies, the rate of emergency D&C was lower (3.6% vs. 9.8%, p = 0.001), compared to spontaneous group.
CONCLUSION
CONCLUSIONS
In cases of medical treatment for EPL, IVF pregnancies had no differences in rates of treatment failure compared to spontaneous pregnancies. That being said, IVF pregnancies have lower chances to undergo emergency D&C, compared to spontaneous pregnancies.
Identifiants
pubmed: 38478159
doi: 10.1007/s00404-024-07423-3
pii: 10.1007/s00404-024-07423-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM (2009) A Comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 353(8):761–769. https://doi.org/10.1056/NEJMoa044064
doi: 10.1056/NEJMoa044064
Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L (2006) Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 332(7552):1235. https://doi.org/10.1136/bmj.38828.593125.2F
doi: 10.1136/bmj.38828.593125.2F
pubmed: 16707509
pmcid: 1471967
Mizrachi Y, Dekalo A, Gluck O, Miremberg H, Dafna L, Feldstein O et al (2017) Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial. Hum Reprod 32(6):1202–1207
doi: 10.1093/humrep/dex074
pubmed: 28402415
Machtinger R, Stockheim D, Seidman DS, Lerner-Geva L, Dor J, Schiff E, Shulman A (2009) Medical treatment with misoprostol for early failure of pregnancies after assisted reproductive technology: a promising treatment option. Fertil Steril 91(5):1881–1885. https://doi.org/10.1016/j.fertnstert.2008.02.001
doi: 10.1016/j.fertnstert.2008.02.001
pubmed: 18455163
Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ (2020) Recurrent pregnancy loss. Nat Rev Dis Primers 6(1):98
doi: 10.1038/s41572-020-00228-z
pubmed: 33303732
Salmanian B, Fox KA, Arian SE, Erfani H, Clark SL, Aagaard KM, Detlefs SE, Aalipour S, Espinoza J, Nassr AA, Gibbons WE, Shamshirsaz AA, Belfort MA, Shamshirsaz AA (2020) In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol 223(4):568.e1-568.e5. https://doi.org/10.1016/j.ajog.2020.04.026
doi: 10.1016/j.ajog.2020.04.026
pubmed: 32360847
Odeh M, Tendler R, Kais M, Maximovsky O, Ophir E, Bornstein J (2010) Early pregnancy failure: factors affecting successful medical treatment. Isr Med Assoc J 12:325–328
pubmed: 20928983
Creinin MD, Huang X, Westhoff C, Barnhart KT, Gilles JM, Zhang J (2007) Factors related to successful misoprostol treatment for early pregnancy failure. Obstet Gynecol 107(4):901–907
doi: 10.1097/01.AOG.0000206737.68709.3e
Doubilet PM, Benson CB, Bourne T, Blaivas M (2014) Diagnostic criteria for nonviable pregnancy early in the first trimester. Ultrasound Q 30:3–9
doi: 10.1097/RUQ.0000000000000060
pubmed: 24901772
Blohm F, Fridén BE, Milsom I, Platz-Christensen JJ, Nielsen S (2005) A randomised double-blind trial comparing misoprostol or placebo in the management of early miscarriage. BJOG 112(8):1090–1095. https://doi.org/10.1111/j.1471-0528.2005.00632.x
doi: 10.1111/j.1471-0528.2005.00632.x
pubmed: 16045523
Stockheim D, Machtinger R, Wiser A, Dulitzky M, Soriano D, Goldenberg M et al (2006) A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril 86(4):956–960. https://doi.org/10.1016/j.fertnstert.2008.02.001
doi: 10.1016/j.fertnstert.2008.02.001
pubmed: 17027362
Banerjee AK, Emembolu JO, Habiba M (2013) The association between serum progesterone and outcome of medical management of early fetal demise: a pilot study. Eur J Obstet Gynecol Reprod Biol 167(1):84–86
Chien LW, Liu WM, Tzeng CR, Au HK (2009) Effect of previous live birth and prior route of delivery on the outcome of early medical. Taiwan J Obstet Gynecol 48(3):225–230
Chill HH, Malyanker N, Karavani G, Haj-Yahya R, Herzberg S, Bahar R et al (2018) Association between uterine position and transvaginal misoprostol treatment for early pregnancy failure. J Obstet Gynaecol Res 44(2):248–252
doi: 10.1111/jog.13512
pubmed: 29094502
Vejborg TS, Nilas L, Rbye CRØ (2007) Medical management of first-trimester miscarriage according to ultrasonographic findings. Acta Obstet Gynecol Scand 86(5):604–609
doi: 10.1080/00016340701288609
pubmed: 17464591
Hamel C, Coppus S, van den Berg J, Hink E, van Seeters J, van Kesteren P et al (2021) Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the triple M trial): a double-blind placebo-controlled randomised trial. EClinicalMedicine 1(32):100724
Chu JJ, Devall AJ, Beeson LE, Hardy P, Cheed V, Sun Y et al (2020) Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet 396:770–778
doi: 10.1016/S0140-6736(20)31788-8
pubmed: 32853559
pmcid: 7493715
Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT (2018) Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med 378(23):2161–2170. https://doi.org/10.1056/NEJMoa1715726
doi: 10.1056/NEJMoa1715726
pubmed: 29874535
pmcid: 6437668
Sonalkar S, Koelper N, Creinin MD, Atrio JM, Sammel MD, McAllister A et al (2020) Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of treatment success from a randomized trial. Am J Obstet Gynecol 223(4):551.e1-551.e7. https://doi.org/10.1016/j.ajog.2020.05.051
doi: 10.1016/j.ajog.2020.05.051
pubmed: 32305259
National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE Guideline [NG126]. Published date: December 2019. https://www.nice.org.uk/guidance/ng126/chapter/Recommendations#management-of-miscarriage . Accessed 13 Mar 2022
World Health Organization (2018) Medical management of abortion. World Health Organization, Geneva
The Israeli Association of Obstetrics and Gynecology (2017) The use of misoprostol in gynecologic procedure
Reeves MF, Palomaki GJ, Bilodeau JE, Creinin MD (2004) Ultrasonographic endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 86(1):22–26
doi: 10.1016/j.ijgo.2004.02.004
Lusink V, Wong C, de Vries B, Ludlow J, Hospital PA (2018) Medical management of miscarriage: predictive factors of success. J Obstet Gynaecol Can 40(6):590–593
Aboulghar MA, Aboulghar MA (2022) Placental pathology after assisted reproduction: impact on the outcome of pregnancy. Fertil Steril 117:769–770
doi: 10.1016/j.fertnstert.2022.01.026
pubmed: 35256189